Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7037378 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL17641091 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL30438065 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL4823593 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL18257718 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL25357815 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL31528885 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL1765926 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL4339424 | 1.00 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL639531 | 0.98 | SMYD2 (0.37) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECH LIMITED (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| WO-2025080049-A1 | COMPOUND FOR INHIBITING ATX, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING OR TREATING ATX ACTIVITY-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2025-04-17 | — | — | WO | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | EMORY UNIVERSITY (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-115667264-A | Novel imidazo-pyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| EP-1638544-B1 | KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2007-12-05 | — | — | EP | disclosed |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| CN-1585746-A | Inhibitors of beta-amyloid production and secretion | DAIICHI SEIYAKU CO (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-0575494-A4 | — | — | 1994-04-20 | — | — | EP | disclosed |
| EP-0575494-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016104-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137703-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, KRAS, O60361 | SMYD2 4308/4885CYP3A4 2558/4885HTT 3312/4885 |
| US-20230295070-A1 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-11691939-B2 | Modulators of liver receptor homologue 1 (LRH-1) and uses | NR1H2, NR1H3, NR1H4 | SMYD2 1285/4885CYP3A4 2300/4885HTT 3051/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | SMYD2 2373/4885CYP3A4 3661/4885HTT 144/4885 |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | APP, PSEN1, PSEN2 | SMYD2 2291/4885CYP3A4 3053/4885HTT 8/4885 |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | APP, IAPP, BACE1 | SMYD2 4482/4885CYP3A4 2566/4885HTT 35/4885 |
| US-20070027112-A1 | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions | OXER1, ESRRA, NR5A1 | SMYD2 4290/4885CYP3A4 1511/4885HTT 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.